Prasugrel is named as an intervention in 6 current clinical trials in our Poland, Ireland, Spain, Norway, Netherlands, Switzerland, Brazil and South Korea registers. 5 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1). The most-studied condition is Coronary Artery Disease. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Prasugrel. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)
2026-525933-22-00 · Cardiovascular Diseases
|
Phase 4 | Ongoing | Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Spain, Norway |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
7 single-substance products containing Prasugrel on the HPRA medicines list.
No entry for Prasugrel in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 1 |
| J.P.S Henriques | 1 |
| Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o | 1 |
| Cardiocentro Ticino | 1 |
| Hospital Israelita Albert Einstein | 1 |
| Asan Medical Center | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
6 current trials in our Poland, Ireland, Spain, Norway, Netherlands, Switzerland, Brazil and South Korea registers name Prasugrel as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 6 trials are recruiting: 2 with sites in Poland, 1 with sites in Ireland, 1 with sites in Spain, 1 with sites in Norway, 1 with sites in Netherlands, 1 with sites in Switzerland and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1), J.P.S Henriques (1), Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o (1) and Cardiocentro Ticino (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Yes. The HPRA medicines list includes 7 single-substance products containing Prasugrel, for example Prasugrel Accord 10 mg film-coated tablets (Accord Healthcare Ireland Ltd.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Prasugrel has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prasugrel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prasugrel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prasugrel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.